Eerad Raises $22.0M Series A

F2

F2 is the compounding intelligence platform for private markets. Purpose-built for private credit and commercial banking, F2 powers how investment teams screen, diligence, underwrite, and monitor deals — turning every transaction into a proprietary advantage that makes the firm smarter over time. At the core is Institutional Knowledge: F2 ingests your firm's IC memos, models, CIMs, and CRM data into a living, queryable library of past judgment. Teams pull precedents in minutes, surface how the firm previously evaluated a sector or sponsor, and underwrite with the pattern recognition of their most experienced MD — and every new deal flows back in automatically, so the library compounds. Unlike general-purpose AI, F2 is Excel-native, running a real Excel engine under the hood with live formulas, dependency tracking, and Audit Mode that traces every number back to its source. F2 ranks #1 on SpreadsheetBench, the industry standard for spreadsheet AI. SOC 2 Type 1 & Type 2 certified and GDPR compliant, with zero data retention and no model training on customer data. Today, more than 15,000 deals are underwritten on F2 annually across firms managing over $400B in client assets. Headquartered in New York City, F2 is backed by leading investors including NFX, Left Lane Capital, and Y Combinator.

Biossil

Biossil is an applied AI drug discovery platform founded to develop targeted therapies for biologically defined patient sub-populations. Our focus is on diseases for which traditional drug discovery has been challenged by population variability.

MeantToBe.Me

MeantToBe.Me | 14 followers on LinkedIn. I help people see themselves in a new light and become what they were always meant to be.